A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients(655 views) D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S
Int J Cancer (ISSN: 0020-7136), 2014 Jul 15; 135(2): 379-390.
Keywords: Cxcr4, Outcome, Predictive Model, Preoperative Radio Chemotherapy, Rectal Cancer, Capecitabine, Chemokine Receptor Cxcr4, Fluorouracil, Folinic Acid, Oxaliplatin, Raltitrexed, Stromal Cell Derived Factor 1, Adjuvant Chemoradiotherapy, Adult, Advanced Cancer, Area Under The Curve, Article, Cancer Prognosis, Cancer Recurrence, Cancer Resistance, Cancer Risk, Cancer Staging, Cancer Survival, Clinical Evaluation, Clinical Feature, Controlled Study, Female, High Risk Patient, Human, Human Tissue, Immunohistochemistry, Major Clinical Study, Multiple Cycle Treatment, Outcome Assessment, Preoperative Period, Priority Journal, Protein Expression, Protein Function, Rectum Cancer, Recurrence Free Survival, Recurrence Risk, Risk Assessment, Risk Factor, Area Under Curve, Chemokine Cxcl12, Disease-Free Survival, Drug Resistance, Neoplasm, Kaplan-Meier Estimate, Middle Aged, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Neoplasm Staging, Proportional Hazards Models, Radiation Tolerance, Rectal Neoplasms, Roc Curve, Tumor Markers, Biological, Chemokine Cxcl12 Metabolism, Neoplasm Physiology, Local Metabolism Mortality Pathology, Cxcr Metabolism, Cxcr4 Metabolism, Rectal Neoplasms Metabolism Mortality Pathology, Biological Analysis,
Affiliations: *** IBB - CNR ***
Department of Oncological Immunology, Istituto Nazionale per Lo Studio e la Cura Dei Tumori Fondazione Giovanni Pascale, IRCCS-ITALIA, via M. Semmola, 80131 Naples, Italy
Department of Gastrointestinal Medical Oncology, Istituto Nazionale per Lo Studio e la Cura Dei Tumori Fondazione Giovanni Pascale, IRCCS-ITALIA, via M. Semmola, 80131 Naples, Italy
Department of Pathology, Istituto Nazionale per Lo Studio e la Cura Dei Tumori Fondazione Giovanni Pascale, IRCCS-ITALIA, via M. Semmola, 80131 Naples, Italy
Department of Surgical Oncology, Istituto Nazionale per Lo Studio e la Cura Dei Tumori Fondazione Giovanni Pascale, IRCCS-ITALIA, via M. Semmola, 80131 Naples, Italy
Department of Radiation Oncology, Istituto Nazionale per Lo Studio e la Cura Dei Tumori Fondazione Giovanni Pascale, IRCCS-ITALIA, via M. Semmola, 80131 Naples, Italy
Institute of Biostructures and Bioimages, National Council of Research (CNR), via T. de Amicis 95, 80145 Naples, Italy
Department of Biomorphological and Functional Science, Federico II University School of Medicine, via S. Pansini 5, 80131 Naples, Italy
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University School of Medicine, via S. Pansini 5, 80131 Naples, Italy
Department of Diagnostic Imaging and Radiation Oncology, Federico II University School of Medicine, via S. Pansini 5, 80131 Naples, Italy
References: Not available.
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients
No results.
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients